The global health landscape is evolving with Brazil battling bird flu-related trade restrictions, Nestle USA eliminating ...

'None of this would matter without you': IAF’s Shubhanshu Shukla’s note to wife before space launch Emergency 1975: The Court ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Viatris will likely encounter additional write-downs and impairments, along with macroeconomic headwinds. Click here to find ...

At least 29% of young adults in Delhi show signs of lung damage in routine CT scans, including bronchiectasis and emphysema, ...

Tata Group first Indian brand over the $30 billion value mark, Eternal joins the top 50 list Harvard liver specialist suggests consuming 4 snacks weekly to reverse fatty liver Amid speculation, ...

Danish pharma giant Novo Nordisk has brought its weight-loss drug Wegovy to India. This follows US company Eli Lilly's launch ...

Weight loss drugs help manage blood sugar levels by mimicking two important hormones GLP-1 (glucagon-like peptide-1) and GIP ...

The Weight Loss Revolution— that’s released on Wednesday provides a detailed insight into these weight management drugs and ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

COPENHAGEN - Danish drugmaker Novo Nordisk will launch its weight-loss drug Wegovy in India without any supply constraints, a ...

Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose up to 20 per cent body weight. But is it safe? Experts answer.